Drug Approval | January 05, 2025
CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
The hospital in association with ‘We Warriors’ and ‘Dev Bhumi Rakshak Foundation’ organized First Aid and CPR training session for youngsters and volunteers
Subscribe To Our Newsletter & Stay Updated
